WASHINGTON, D.C. - A panel of the District of Columbia U.S. Circuit Court of Appeals on Jan. 4 affirmed that the secretary of defense reasonably interpreted a federal regulation aimed at curbing the cost of prescription drugs for military families to impose involuntary price caps on prescription drugs and to impose retroactive rebate liability on pharmaceutical manufacturers (Coalition for Common Sense in Government Procurement v. United States of America, et al., No. 11-5350, D.C. Cir.; 2013 U.S. App. LEXIS 216).